Evidence map›Paper›PMID 34499652›Full record

ArticlePloS one2021

Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines.

Adam V Wisnewski, Carrie A Redlich, Jian Liu, Kathy Kamath, Queenie-Ann Abad, Richard F Smith, Louis Fazen, Romero Santiago, Julian Campillo Luna, Brian Martinez and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Modular nanoarray vaccine for SARS-CoV-2.Nanomedicine : nanotechnology, biology, and medicine · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Adam V WisnewskiDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.ORCID 0000-0003-2461-9409
Carrie A RedlichDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Jian LiuDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Kathy KamathSerimmune, Inc., Goleta, CA, United States of America.
Queenie-Ann AbadDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Richard F SmithDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Louis FazenDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Romero SantiagoDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Julian Campillo LunaDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.ORCID 0000-0001-8509-0700
Brian MartinezSerimmune, Inc., Goleta, CA, United States of America.
Elizabeth Baum-JonesSerimmune, Inc., Goleta, CA, United States of America.
Rebecca WaitzSerimmune, Inc., Goleta, CA, United States of America.
Winston A HaynesSerimmune, Inc., Goleta, CA, United States of America.
John C ShonSerimmune, Inc., Goleta, CA, United States of America.
Yale University · USSerimmune (United States) · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
ACL HHS T03OH008607NCATS NIH HHS UL1 TR001863NIOSH CDC HHS T01 OH008607NIOSH CDC HHS T03 OH008607
6 · The paper itself

Abstract

Reverse vaccinology is an evolving approach for improving vaccine effectiveness and minimizing adverse responses by limiting immunizations to critical epitopes. Towards this goal, we sought to identify immunogenic amino acid motifs and linear epitopes of the SARS-CoV-2 spike protein that elicit IgG in COVID-19 mRNA vaccine recipients. Paired pre/post vaccination samples from N = 20 healthy adults, and post-vaccine samples from an additional N = 13 individuals were used to immunoprecipitate IgG targets expressed by a bacterial display random peptide library, and preferentially recognized peptides were mapped to the spike primary sequence. The data identify several distinct amino acid motifs recognized by vaccine-induced IgG, a subset of those targeted by IgG from natural infection, which may mimic 3-dimensional conformation (mimotopes). Dominant linear epitopes were identified in the C-terminal domains of the S1 and S2 subunits (aa 558-569, 627-638, and 1148-1159) which have been previously associated with SARS-CoV-2 neutralization in vitro and demonstrate identity to bat coronavirus and SARS-CoV, but limited homology to non-pathogenic human coronavirus. The identified COVID-19 mRNA vaccine epitopes should be considered in the context of variants, immune escape and vaccine and therapy design moving forward.

Indexed as

Epitope MappingAmino Acid MotifsAmino Acid SequenceCoronavirus InfectionsCOVID-19COVID-19 VaccinesHumansImmunoglobulin GSARS-CoV-2Sequence AlignmentSpike Glycoprotein, CoronavirusCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID34499652
PMCPMC8428655
OpenAlexW3196552088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.